SCHEMBL19355381

SCHEMBL19355381

CNC(=O)c1ccc(CCNc2cc(-c3ccc(Nc4ccncc4)nc3)ncn2)c(OC)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 10/20 0.43
BCR P11274 10/20 0.43
CYP1A2 P05177 5/20 0.42
CYP3A4 P08684 5/20 0.42
CLK4 Q9HAZ1 5/20 0.42
CYP2D6 P10635 4/20 0.42
USP2 O75604 3/20 0.42
CYP2C19 P33261 3/20 0.41
HSD17B10 Q99714 2/20 0.41
TSHR P16473 1/20 0.41
ALDH1A1 P00352 2/20 0.40
ALOX15 P16050 1/20 0.40
JAK1 P23458 1/20 0.39
TYK2 P29597 1/20 0.39
BUB1 O43683 1/20 0.39
MEN1 O00255 1/20 0.38
PKM P14618 1/20 0.38
KMT2A Q03164 1/20 0.38
HTR1D P28221 1/20 0.38
HTR1B P28222 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15356521 0.89 CYP1A2 (0.47) ABL1BCRCYP1A2CYP3A4CLK4
SCHEMBL19355397 0.87 CYP1A2 (0.44) ABL1BCRCYP1A2CYP3A4CLK4
SCHEMBL19355388 0.86 CYP1A2 (0.44) ABL1BCRCYP1A2CYP3A4CLK4
SCHEMBL19905232 0.85 CLK4 (0.46) ABL1BCRCYP1A2CYP3A4CLK4
SCHEMBL19355068 0.84 CYP1A2 (0.42) ABL1BCRCYP1A2CYP3A4CLK4
SCHEMBL19355069 0.84 CYP1A2 (0.42) ABL1BCRCYP1A2CYP3A4CLK4
SCHEMBL15343393 0.84 ABL1 (0.41) ABL1BCRCYP1A2CYP3A4CLK4
SCHEMBL16660255 0.84 CYP1A2 (0.49) ABL1BCRCYP1A2CYP3A4CLK4
SCHEMBL19355384 0.84 PDE10A (0.44) ABL1BCRCYP1A2CYP3A4CLK4
SCHEMBL19355452 0.83 HCAR3 (0.45) ABL1BCRCYP1A2CYP3A4CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180193341-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2018-07-12 US disclosed
US-20170258789-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170258789-A1 DNA-PK INHIBITORS POLK, DTYMK, DCK ABL1 713/4885BCR 2305/4885CYP1A2 2215/4885
US-20180193341-A1 DNA-PK INHIBITORS POLK, DTYMK, DCK ABL1 713/4885BCR 2305/4885CYP1A2 2215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.